Carla Carnovale1, Marco Pozzi2, Faizan Mazhar3, Giulia Mosini3, Marta Gentili3, Gabriëlla G A M Peeters3, Emilio Clementi3,2, Sonia Radice3. 1. Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, "Luigi Sacco" University Hospital, Università di Milano, Via GB Grassi 74, 20157, Milan, Italy. carla.carnovale@unimi.it. 2. Scientific Institute IRCCS Eugenio Medea, 23842 Bosisio Parini, Lecco, Italy. 3. Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, "Luigi Sacco" University Hospital, Università di Milano, Via GB Grassi 74, 20157, Milan, Italy.
Abstract
INTRODUCTION: Qualitative studies on drug-drug interactions (DDIs) between anticonvulsants and antibiotics report pharmacokinetic changes that may increase the clinical risks in terms of adverse drug reactions (ADRs) and efficacy. However, no studies have provided a systematic and quantitative analysis of anticonvulsant-antibiotic pharmacokinetic DDIs. To provide such indications, we systematically and critically reviewed the literature on anticonvulsant-antibiotic DDIs in terms of quantitative pharmacokinetic changes and related ADRs. We also investigated less-known interactions for the possible occurrence of clinically relevant events. METHODS: We conducted a systematic review of all reports of DDIs between anticonvulsants and antibiotics assessing pharmacokinetic parameters published until 9 June 2017. RESULTS: We were able to meta-analyse the effect of macrolides on carbamazepine area under the concentration-time curve from time zero to infinity [AUC∞] (+ 34.5 µg/mL*h, p = 0.005, n = 38), clearance (- 2.88 mL/min, p < 0.001, n = 46) and trough plasma concentration [Ct] (+ 8.0 µg/mL, p = 0.002, n = 23), and of carbapenems on valproic acid Ct (- 42.9 µg/mL, p < 0.001, n = 262). Pharmacokinetic parameters with other DDIs were insufficiently reported to allow a statistical analysis. CONCLUSIONS: Therapeutic drug monitoring in patients receiving long-term antiepileptic therapies may help, in specific conditions, to improve safety while preserving efficacy. Such a procedure would also increase scientific information on how pharmacokinetic variations are associated with ADR occurrence, and possibly epileptological outcomes for those DDIs for which available information is suggestive of a relevant effect but is not yet sufficient to draw conclusions.
INTRODUCTION: Qualitative studies on drug-drug interactions (DDIs) between anticonvulsants and antibiotics report pharmacokinetic changes that may increase the clinical risks in terms of adverse drug reactions (ADRs) and efficacy. However, no studies have provided a systematic and quantitative analysis of anticonvulsant-antibiotic pharmacokinetic DDIs. To provide such indications, we systematically and critically reviewed the literature on anticonvulsant-antibiotic DDIs in terms of quantitative pharmacokinetic changes and related ADRs. We also investigated less-known interactions for the possible occurrence of clinically relevant events. METHODS: We conducted a systematic review of all reports of DDIs between anticonvulsants and antibiotics assessing pharmacokinetic parameters published until 9 June 2017. RESULTS: We were able to meta-analyse the effect of macrolides on carbamazepine area under the concentration-time curve from time zero to infinity [AUC∞] (+ 34.5 µg/mL*h, p = 0.005, n = 38), clearance (- 2.88 mL/min, p < 0.001, n = 46) and trough plasma concentration [Ct] (+ 8.0 µg/mL, p = 0.002, n = 23), and of carbapenems on valproic acid Ct (- 42.9 µg/mL, p < 0.001, n = 262). Pharmacokinetic parameters with other DDIs were insufficiently reported to allow a statistical analysis. CONCLUSIONS: Therapeutic drug monitoring in patients receiving long-term antiepileptic therapies may help, in specific conditions, to improve safety while preserving efficacy. Such a procedure would also increase scientific information on how pharmacokinetic variations are associated with ADR occurrence, and possibly epileptological outcomes for those DDIs for which available information is suggestive of a relevant effect but is not yet sufficient to draw conclusions.
Authors: C Hiemke; N Bergemann; H W Clement; A Conca; J Deckert; K Domschke; G Eckermann; K Egberts; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; G Hefner; R Helmer; G Janssen; E Jaquenoud; G Laux; T Messer; R Mössner; M J Müller; M Paulzen; B Pfuhlmann; P Riederer; A Saria; B Schoppek; G Schoretsanitis; M Schwarz; M Silva Gracia; B Stegmann; W Steimer; J C Stingl; M Uhr; S Ulrich; S Unterecker; R Waschgler; G Zernig; G Zurek; P Baumann Journal: Pharmacopsychiatry Date: 2017-09-14 Impact factor: 5.788
Authors: Jerry J Shih; Julia B Whitlock; Nicole Chimato; Emily Vargas; Steven C Karceski; Ryan D Frank Journal: Epilepsy Behav Date: 2017-02-23 Impact factor: 2.937